Cargando…

Immunogenic cell death-associated biomarkers classification predicts prognosis and immunotherapy efficacy in pancreatic ductal adenocarcinoma

INTRODUCTION: Immunogenic cell death (ICD) is a sort of regulated cell death (RCD) sufficient to trigger an adaptive immunological response. According to the current findings, ICD has the capacity to alter the tumor immune microenvironment by generating danger signals or damage-associated molecular...

Descripción completa

Detalles Bibliográficos
Autores principales: Peng, Wenguang, Yang, Jiarui, Xia, Long, Qian, Xiangjun, Long, Guojie, Zhang, Hao, Xie, Jiancong, Zhao, Junzhang, Zhang, Lei, Pan, Weidong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10098015/
https://www.ncbi.nlm.nih.gov/pubmed/37064149
http://dx.doi.org/10.3389/fonc.2023.1178966
_version_ 1785024699668889600
author Peng, Wenguang
Yang, Jiarui
Xia, Long
Qian, Xiangjun
Long, Guojie
Zhang, Hao
Xie, Jiancong
Zhao, Junzhang
Zhang, Lei
Pan, Weidong
author_facet Peng, Wenguang
Yang, Jiarui
Xia, Long
Qian, Xiangjun
Long, Guojie
Zhang, Hao
Xie, Jiancong
Zhao, Junzhang
Zhang, Lei
Pan, Weidong
author_sort Peng, Wenguang
collection PubMed
description INTRODUCTION: Immunogenic cell death (ICD) is a sort of regulated cell death (RCD) sufficient to trigger an adaptive immunological response. According to the current findings, ICD has the capacity to alter the tumor immune microenvironment by generating danger signals or damage-associated molecular patterns (DAMPs), which may contribute in immunotherapy. It would be beneficial to develop ICD-related biomarkers that classify individuals depending on how well they respond to ICD immunotherapy. METHODS AND RESULTS: We used consensus clustering to identify two ICD-related groupings. The ICD-high subtype was associated with favorable clinical outcomes, significant immune cell infiltration, and powerful immune response signaling activity. In addition, we developed and validated an ICD-related prognostic model for PDAC survival based on the tumor immune microenvironment. We also collected clinical and pathological data from 48 patients with PDAC, and patients with high EIF2A expression had a poor prognosis. Finally, based on ICD signatures, we developed a novel PDAC categorization method. This categorization had significant clinical implications for determining prognosis and immunotherapy. CONCLUSION: Our work emphasizes the connections between ICD subtype variations and alterations in the immune tumor microenvironment in PDAC. These findings may help the immune therapy-based therapies for patients with PDAC. We also created and validated an ICD-related prognostic signature, which had a substantial impact on estimating patients' overall survival times (OS).
format Online
Article
Text
id pubmed-10098015
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-100980152023-04-14 Immunogenic cell death-associated biomarkers classification predicts prognosis and immunotherapy efficacy in pancreatic ductal adenocarcinoma Peng, Wenguang Yang, Jiarui Xia, Long Qian, Xiangjun Long, Guojie Zhang, Hao Xie, Jiancong Zhao, Junzhang Zhang, Lei Pan, Weidong Front Oncol Oncology INTRODUCTION: Immunogenic cell death (ICD) is a sort of regulated cell death (RCD) sufficient to trigger an adaptive immunological response. According to the current findings, ICD has the capacity to alter the tumor immune microenvironment by generating danger signals or damage-associated molecular patterns (DAMPs), which may contribute in immunotherapy. It would be beneficial to develop ICD-related biomarkers that classify individuals depending on how well they respond to ICD immunotherapy. METHODS AND RESULTS: We used consensus clustering to identify two ICD-related groupings. The ICD-high subtype was associated with favorable clinical outcomes, significant immune cell infiltration, and powerful immune response signaling activity. In addition, we developed and validated an ICD-related prognostic model for PDAC survival based on the tumor immune microenvironment. We also collected clinical and pathological data from 48 patients with PDAC, and patients with high EIF2A expression had a poor prognosis. Finally, based on ICD signatures, we developed a novel PDAC categorization method. This categorization had significant clinical implications for determining prognosis and immunotherapy. CONCLUSION: Our work emphasizes the connections between ICD subtype variations and alterations in the immune tumor microenvironment in PDAC. These findings may help the immune therapy-based therapies for patients with PDAC. We also created and validated an ICD-related prognostic signature, which had a substantial impact on estimating patients' overall survival times (OS). Frontiers Media S.A. 2023-03-30 /pmc/articles/PMC10098015/ /pubmed/37064149 http://dx.doi.org/10.3389/fonc.2023.1178966 Text en Copyright © 2023 Peng, Yang, Xia, Qian, Long, Zhang, Xie, Zhao, Zhang and Pan https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Peng, Wenguang
Yang, Jiarui
Xia, Long
Qian, Xiangjun
Long, Guojie
Zhang, Hao
Xie, Jiancong
Zhao, Junzhang
Zhang, Lei
Pan, Weidong
Immunogenic cell death-associated biomarkers classification predicts prognosis and immunotherapy efficacy in pancreatic ductal adenocarcinoma
title Immunogenic cell death-associated biomarkers classification predicts prognosis and immunotherapy efficacy in pancreatic ductal adenocarcinoma
title_full Immunogenic cell death-associated biomarkers classification predicts prognosis and immunotherapy efficacy in pancreatic ductal adenocarcinoma
title_fullStr Immunogenic cell death-associated biomarkers classification predicts prognosis and immunotherapy efficacy in pancreatic ductal adenocarcinoma
title_full_unstemmed Immunogenic cell death-associated biomarkers classification predicts prognosis and immunotherapy efficacy in pancreatic ductal adenocarcinoma
title_short Immunogenic cell death-associated biomarkers classification predicts prognosis and immunotherapy efficacy in pancreatic ductal adenocarcinoma
title_sort immunogenic cell death-associated biomarkers classification predicts prognosis and immunotherapy efficacy in pancreatic ductal adenocarcinoma
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10098015/
https://www.ncbi.nlm.nih.gov/pubmed/37064149
http://dx.doi.org/10.3389/fonc.2023.1178966
work_keys_str_mv AT pengwenguang immunogeniccelldeathassociatedbiomarkersclassificationpredictsprognosisandimmunotherapyefficacyinpancreaticductaladenocarcinoma
AT yangjiarui immunogeniccelldeathassociatedbiomarkersclassificationpredictsprognosisandimmunotherapyefficacyinpancreaticductaladenocarcinoma
AT xialong immunogeniccelldeathassociatedbiomarkersclassificationpredictsprognosisandimmunotherapyefficacyinpancreaticductaladenocarcinoma
AT qianxiangjun immunogeniccelldeathassociatedbiomarkersclassificationpredictsprognosisandimmunotherapyefficacyinpancreaticductaladenocarcinoma
AT longguojie immunogeniccelldeathassociatedbiomarkersclassificationpredictsprognosisandimmunotherapyefficacyinpancreaticductaladenocarcinoma
AT zhanghao immunogeniccelldeathassociatedbiomarkersclassificationpredictsprognosisandimmunotherapyefficacyinpancreaticductaladenocarcinoma
AT xiejiancong immunogeniccelldeathassociatedbiomarkersclassificationpredictsprognosisandimmunotherapyefficacyinpancreaticductaladenocarcinoma
AT zhaojunzhang immunogeniccelldeathassociatedbiomarkersclassificationpredictsprognosisandimmunotherapyefficacyinpancreaticductaladenocarcinoma
AT zhanglei immunogeniccelldeathassociatedbiomarkersclassificationpredictsprognosisandimmunotherapyefficacyinpancreaticductaladenocarcinoma
AT panweidong immunogeniccelldeathassociatedbiomarkersclassificationpredictsprognosisandimmunotherapyefficacyinpancreaticductaladenocarcinoma